Psychosis in Parkinson’s and Alzheimer’s disease Epidemiology

DelveInsight’s ‘Psychosis in Parkinson’s and Alzheimer’s disease – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the Psychosis in Parkinson’s and Alzheimer’s disease, historical and forecasted epidemiology as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Psychosis in Parkinson’s and Alzheimer’s Disease Understanding

Psychosis is a severe mental condition in which thoughts and emotions are so affected that contact is lost with external reality. As per the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and International Classification of Diseases, Tenth Revision (ICD-10), psychosis is a syndrome rooted in several disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and bipolar disorder with psychotic features.

Psychosis can be categorized into three broad groups: idiopathic psychosis, psychosis due to medical conditions (including neurodegenerative disorders), and toxic psychosis (due to substances of abuse, prescribed medications, or toxins).

Psychosis in Parkinson’s disease, a common phenomenon in Parkinson’s disease patients, correlates with depression and dementia and contributes to considerable stress and burnout for the caregiver. It is characterized by visual hallucinations and/or other psychotic symptoms, including auditory hallucinations, delusions, or illusions, and is now considered closely associated with Parkinson’s disease.

Psychosis in Parkinson’s disease is associated with high patient mortality and morbidity, including decreased health-promoting behaviors and longer nursing home stays. Furthermore, a relationship exists between the development of psychosis in Parkinson’s disease and other psychiatric diagnoses, including depression and dementia.

Alzheimer’s disease, a neurodegenerative disorder that destroys memory and other important mental functions in an individual, is commonly termed dementia worldwide. Psychosis is common in Alzheimer’s and can emerge as part of the neurodegenerative disease process during the mild cognitive impairment stage or even earlier. Studies suggest more than two million people in the US have dementia-related psychosis and struggle to deal with a wide range of psychotic episodes in day-to-day life.

Dopamine and glutamate are implicated in the pathophysiology of psychotic symptoms; psychosis is hallucinations, delusions, and delusional misidentification syndromes. Practical guidance on evaluating and treating these conditions is drawn from practice guidelines that professional societies and other international organizations promulgated, supplemented with findings published in more recent meta-analyses and systematic reviews.

Psychosis in Parkinson’s and Alzheimer’s Disease Diagnosis

Despite various etiologic and physiological hypotheses, the diagnosis of psychotic disorders is clinical and therefore based predominantly on the patient’s history, observed behavior, subjective reports, and results of the mental status examination. Diagnostic tests, including neuroimaging and electroencephalographic (EEG), genotypic, toxicological, and serologic assessments, are usually performed only in selected patients presenting with a first episode of psychosis or psychotic symptoms associated with pre-existing neurodegenerative diseases, other medical conditions, or substance abuse.

Continued in the report…..     

Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of Parkinson’s and Alzheimer’s disease, gender-specific cases of Parkinson’s and Alzheimer’s disease, age-specific cases of Parkinson’s and Alzheimer’s disease, and diagnosed prevalent cases of psychosis in Parkinson’s and Alzheimer’s disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

Psychosis in Parkinson’s and Alzheimer’s Disease Detailed Epidemiology Segmentation

• In 2022, there were approximately 2,608,120 diagnosed prevalent cases of Parkinson’s disease in the 7MM. The US accounted for nearly 45% of the total diagnosed prevalent cases of Parkinson’s disease in the 7MM.
• In EU4 and the UK, males diagnosed with Parkinson’s disease are higher in number than females. In 2022, the cases of Parkinson’s disease among males in EU4 and the UK were reported to be approximately 643,961, while there were around 526,877 cases among the female population. These numbers are expected to rise during the study period (2021-2034).
• In Japan, the population in the age group =70 years accounted for the highest number of diagnosed Parkinson’s disease cases making around 76% of the total diagnosed prevalent cases of Parkinson’s disease in the country, while the <50 age group had the least cases in 2022.
• In 2022, there were approximately 15,083,370 diagnosed prevalent cases of Alzheimer’s disease in the 7MM. The US accounted for nearly 41% of the total diagnosed prevalent cases of Alzheimer’s disease in the 7MM.
• In the 7MM, females account for a higher percentage of diagnosed prevalent cases of Alzheimer’s disease than males. In 2022, approximately 2,165,199 males and 4,021,085 females were diagnosed with prevalent cases of Alzheimer’s disease in the US.
• In 2022, there were approximately 537,743, 704,051, 230,354, and 38,367 cases of Alzheimer’s disease in the age groups =85, 75–84, 65–74, and <65 in Germany, which account for the largest number among the EU4 and the UK. These cases are expected to increase during the study period.
• In 2022, the diagnosed prevalent cases of psychosis in Parkinson’s disease were estimated to be approximately 857,765 cases in the 7MM. These cases are expected to increase by 2034 at a CAGR of 2.1% during the study period.
• In 2022, the diagnosed prevalent cases of psychosis in Alzheimer’s disease were estimated to be approximately 5,879,571 cases in the 7MM. These cases are expected to increase by 2034 at a CAGR of 2.4% during the study period.
• Among the 7MM, the US accounted for approximately 34% of the total diagnosed prevalent cases of psychosis in Parkinson’s and Alzheimer’s disease in 2022, which is expected to increase further during the study period.

Scope of the Report

• The report covers a descriptive overview of psychosis in Parkinson’s and Alzheimer’s disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The report assesses the disease risk and burden of psychosis in Parkinson’s and Alzheimer’s disease.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalence of Parkinson’s and Alzheimer’s disease, the gender-specific diagnosed prevalence of Parkinson’s and Alzheimer’s disease, the age-specific diagnosed prevalence of Parkinson’s and Alzheimer’s disease, and the total diagnosed prevalence of psychosis in Parkinson’s and Alzheimer’s disease.

Report Highlights

• Ten years Forecast of Psychosis in Parkinson’s and Alzheimer’s Disease
• The 7MM coverage
• Diagnosed Prevalent Cases of Parkinson’s and Alzheimer’s Disease
• Gender-specific Cases of Parkinson’s and Alzheimer’s Disease
• Age-specific Cases of Parkinson’s and Alzheimer’s Disease
• Diagnosed Prevalent Cases of Psychosis in Parkinson’s and Alzheimer’s Disease

Key Questions Answered

• What are the disease risk and burdens of psychosis in Parkinson’s and Alzheimer’s disease?
• What is the historical psychosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of psychosis in Parkinson’s and Alzheimer’s disease at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with psychosis in Parkinson’s and Alzheimer’s disease?
• Out of the countries mentioned above, which country would have the highest prevalent population of psychosis in Parkinson’s and Alzheimer’s disease during the forecast period (2025-2034)?
• At what CAGR is the population expected to grow across the 7MM forecast period (2025-2034)?

Reasons to Buy

The psychosis in Parkinson’s and Alzheimer’s disease report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM psychosis in Parkinson’s and Alzheimer’s disease epidemiology forecast.
• The psychosis in Parkinson’s and Alzheimer’s disease epidemiology report and model were written and developed by Master’s and Ph.D. level epidemiologists.
• The psychosis in Parkinson’s and Alzheimer’s disease epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by the Segmentation
• Factors Driving Growth in a Specific Patient Population